Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...
The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...
has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and tolerability of QUTENZA ® (capsaicin) 8% topical system in post-surgical neuropathic ...
With a history of spinal injury and having not undergone a surgical stabilization, a syrinx was suspected. A magnetic resonance imaging (MRI) study of the patient's cervical and thoracic spine was ...
DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") , a life sciences company focused on molecular hydrogen and AI diagnostics for brain health, today announced that it has filed a provisional ...
Annovis Bio Inc. ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and ...
has been shown to block ectopic discharges in axotomized sensory fibers and, thereby, may be of great interest for modulating some peripheral or central neuropathic pain symptoms. [15] ...
The National Comprehensive Cancer Network (NCCN)-;an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven guidelines for care-;announces the publication of ...